Perspective Therapeutics Secures $164M, VMT-α-NET Achieves 76% Progression-Free Rate
Perspective Therapeutics reported FY2025 cash and short-term investments of $145M plus $164M equity proceeds, funding operations into late 2027. Lead radiopharmaceutical VMT-α-NET showed no dose-limiting toxicities and achieved 76% progression-free rate with 39% response rate in 56 patients.
1. Financial Position and Runway
As of December 31, 2025, Perspective Therapeutics held approximately $145 million in cash, cash equivalents and short-term investments, and raised an additional $164 million in net proceeds from a subsequent equity offering. This combined $309 million capital is expected to fund current planned clinical milestones and operational investments into late 2027.
2. VMT-α-NET Safety and Efficacy Data
Interim safety data from 56 VMT-α-NET patients showed no dose-limiting toxicities, serious renal complications, dysphagia or clinically significant myelosuppression; Grade 3 or higher events occurred in 37.5%, including one transient Grade 4. Efficacy analysis of 25 patients reported 76% progression-free survival and a 39% response rate, with deepening tumor responses noted.
3. Outlook and Regulatory Path
Data across all dose levels support development optionality and a robust clinical evidence package for presentations and regulatory engagement in 2026. Full one-year follow-up for all 46 Cohort 2 patients is expected by mid-2026, and clinical updates for all three pipeline programs will be submitted for conference presentations throughout the year.